A detailed history of Citigroup Inc transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Citigroup Inc holds 144,706 shares of CORT stock, worth $8.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
144,706
Previous 96,436 50.05%
Holding current value
$8.12 Million
Previous $3.13 Million 113.66%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$29.51 - $46.26 $1.42 Million - $2.23 Million
48,270 Added 50.05%
144,706 $6.69 Million
Q2 2024

Aug 12, 2024

SELL
$22.21 - $34.48 $233,538 - $362,557
-10,515 Reduced 9.83%
96,436 $3.13 Million
Q1 2024

May 10, 2024

BUY
$21.1 - $27.46 $592,466 - $771,049
28,079 Added 35.6%
106,951 $2.69 Million
Q4 2023

Feb 09, 2024

BUY
$24.82 - $32.88 $671,480 - $889,535
27,054 Added 52.21%
78,872 $2.56 Million
Q3 2023

Nov 09, 2023

SELL
$21.97 - $33.8 $771,498 - $1.19 Million
-35,116 Reduced 40.39%
51,818 $1.41 Million
Q2 2023

Aug 10, 2023

BUY
$21.44 - $25.15 $305,477 - $358,337
14,248 Added 19.6%
86,934 $1.93 Million
Q1 2023

May 11, 2023

SELL
$19.2 - $24.47 $39,782 - $50,701
-2,072 Reduced 2.77%
72,686 $1.57 Million
Q4 2022

Feb 09, 2023

BUY
$19.95 - $29.96 $76,268 - $114,537
3,823 Added 5.39%
74,758 $1.52 Million
Q3 2022

Nov 10, 2022

BUY
$24.7 - $29.12 $53,549 - $63,132
2,168 Added 3.15%
70,935 $1.82 Million
Q2 2022

Aug 10, 2022

SELL
$17.33 - $25.3 $597,434 - $872,192
-34,474 Reduced 33.39%
68,767 $1.64 Million
Q1 2022

May 12, 2022

BUY
$16.53 - $25.21 $222,956 - $340,032
13,488 Added 15.03%
103,241 $2.33 Million
Q4 2021

Feb 10, 2022

BUY
$17.1 - $23.34 $40,971 - $55,922
2,396 Added 2.74%
89,753 $1.78 Million
Q3 2021

Nov 10, 2021

BUY
$19.68 - $22.53 $1.72 Million - $1.97 Million
87,357 New
87,357 $1.72 Million

Others Institutions Holding CORT

About CORCEPT THERAPEUTICS INC


  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $6.01B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.